Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Lantheus Holdings, Inc.

Analysts are intrested in these 5 stocks: ( ($BBY) ), ( ($YARW) ), ( ($AAPL) ), ( ($LNTH) ) and ( ($INTU) ). Here is a breakdown of their recent


Best Buy, Yarrow, Apple, Lantheus, Intuit Trending With Analysts

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexicon Pharmaceuticals (LXRX), Ascendis Pharma (ASND) and Lanthe...

Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Ascendis Pharma (ASND) and Lantheus (LNTH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oculis Holding (OCS) and Lantheus (LNTH). Oculis Holding (OCS) Ne...

Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Lantheus (LNTH)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Autolus Therapeutics (AUTL) and Lantheus (LNTH). A...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL) and Lantheus (LNTH)

Lantheus received a Hold rating and price target from William Blair analyst Andy Hsieh today. According to TipRanks, Hsieh is a 4-star analyst with...

Lantheus (LNTH) was downgraded to a Hold Rating at William Blair

The latest update is out from Lantheus ( ($LNTH) ). On August 3, 2026, Curium US Holdings and Lantheus agreed to a merger in which Curium will acqu...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LNTH	$100.95	-0.12%	2.08M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LNTH	$100.95	-0.1%	2.08M
3
4
5
6

LNTH

LNTH

Get Lantheus Holdings, Inc. Data in Excel

Get Lantheus Holdings, Inc. Data in Excel